Niowave, Inc. Email Format
Pharmaceutical ManufacturingMichigan, United States51-200 Employees
Niowave, Inc. is a Lansing, Michigan-based pharmaceutical manufacturer focused on producing Actinium-225 for next-generation cancer therapies, using a superconducting linear accelerator paired with radiochemistry. This setup aims to provide a reliable and scalable source of Ac-225 while avoiding the use of nuclear reactors or weapons-grade uranium, with automated, small-batch radiochemistry operations that do not require licensing as a nuclear reprocessing facility. The company emphasizes alignment with established radiopharmaceutical supply chains and FDA approval processes for isotope production and distribution. The business operates within the pharmaceutical manufacturing sector, serving pharmaceutical and biotech developers pursuing Ac-225-based treatments and related radiopharmaceutical programs. In 2026 the firm announced expansion of its Lansing footprint, including the construction of a new production facility, and engagement in partnerships to advance radiopharmaceutical programs, such as a collaboration with Aptevo Therapeutics.